Precision Medicine: Advances in Personalizing Cancer Care

On June 25th, 2015, posted in: Cancer 101 by

With hundreds of new cancer therapies in various stages of clinical development, this is one of the most promising and exciting times in clinical cancer research history. Today, effective therapies are being developed that are also more precision-based and less toxic, causing fewer immediate and long-term side-effects for patients.

For decades, cancer research was aimed at treating cancers that were categorized into types based on the size and appearance of malignant cells seen under a microscope. Today, cancer research is increasingly focused on genomics, screening for molecular features that may predict response or resistance to a drug, molecular imaging, studies of genetic factors that may predict drug toxicity, and harnessing the body’s own immune system to fight tumor cells. Scientists have identified and are now exploring entire families of genetic mutations, including the RAS family, which is associated with approximately one-third of all cancers. The use of bioinformatics is enabling research institutions to collaborate in order to gather large volumes of data that can be utilized for basic, clinical and translational cancer research. These are but a few of the new methods scientists are utilizing to revolutionize precision-based cancer research and treatment.

Speakers included:

Wendy K.D. Selig, President, National Coalition for Cancer Research; Founder and Chief Executive Officer, WS Collaborative

Frank McCormick, PhD, FRS, DSc (Hon), Professor Emeritus, David A. Wood Distinguished Professorship of Tumor Biology and Cancer Research, University of San Francisco Helen Diller Comprehensive Cancer Center, and Scientific Director, National Cancer Institute RAS Initiative

William S. Dalton, Ph.D, M.D., Founder and President of M2Gen®, and former President and CEO of the Moffitt Cancer Center, Tampa, Florida

No Responses to “Precision Medicine: Advances in Personalizing Cancer Care”

Leave a Reply